Venture capital fund OneVentures has strengthened its healthcare capability with the appointment of two investment managers.
Intellectual property (IP) and commercial specialist Sakura Holloway and former Shire Pharmaceuticals scout Sarah Meibusch have been recruited to OneVentures.
The appointments see the OneVentures team grow to 10 as it looks to develop the recently launched $140 million Healthcare Fund III.
"The fund is focused on investing in Australian companies commercialising drugs, medical devices and diagnostics in or near clinical development stage," said a statement by the VC fund.
Ms Holloway joins the OneVentures following two years as chief IP counsel at dual-listed Australian/US biotech company Benitec Biopharma Ltd.
Ms Meibusch joins the fund following five years scouting technologies for Shire Pharmaceuticals within Australia, New Zealand, Singapore, Taiwan, Korea and Japan, including sourcing the $300 million Fibrotech deal.
Managing partner and head of OneVentures healthcare practice Paul Kelly said, "The appointment of Sakura and Sarah completes our Healthcare sector investment team providing critical resources to support the first stage of the execution of our OneVentures Healthcare Fund III investment plan.
"OneVenture’s hands-on approach to deal structuring and management requires access to an expert and experienced professional team."